SOLICITATION NOTICE
65 -- Customized plasmid and DNA synthesis, and protein production and purification
- Notice Date
- 8/11/2020 2:00:37 PM
- Notice Type
- Presolicitation
- NAICS
- 325413
— In-Vitro Diagnostic Substance Manufacturing
- Contracting Office
- NATIONAL INSTITUTES OF HEALTH NIAID BETHESDA MD 20892 USA
- ZIP Code
- 20892
- Solicitation Number
- NOI-NIAID-2031238
- Response Due
- 8/20/2020 7:00:00 AM
- Archive Date
- 09/04/2020
- Point of Contact
- Skye Duffner, Phone: 4068026092, Julienne Keiser, Phone: 4063639370
- E-Mail Address
-
skye.duffner@nih.gov, jkeiser@niaid.nih.gov
(skye.duffner@nih.gov, jkeiser@niaid.nih.gov)
- Description
- This is a Notice of Intent, not a request for proposal. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with Genscript USA Inc, Piscataway, NJ 08854 for customized plasmid and DNA synthesis, and protein production and purification. The Biodefense Research Section of the Vaccine Research Center develops vaccines and monoclonal antibody therapies for the treatment of biodefense related pathogens such as Ebola virus, Sudan virus, Bundibugyo virus, Marburg virus and Lassa Fever virus. These efforts require highly purified and specialized protein and antibodies for use as reagents and for the development and testing of therapeutic antibody and vaccine candidates. The services being purchased will provide these reagents and materials. Genscript services are used in the project. They have produced the proteins and antibodies in multiple cell types. Their services must continue to be procured as materials must be produced in the same way with the same quality controls as the previously produced materials. Due to ongoing experiments, future materials will need to be compatible with these past materials to preserve integrity of the data and continuity of science. The required materials will be involved in animal experiments that are performed under high-containment (Bio-Safety Level 4 labs) safety protocols. The BRS requires materials produced with the same quality control measures and protocols to prevent variability of existing data and t prevent having to repeat these experiments in such a high-containment environment. In order to prevent data variability and to use the same critical protocols, we must retain Genscript as the provider for these services to maintain continuity of science and the integrity of the data. No Substitutions are allowed on this project. The Place of performance is 9000 Rockville Pike, Bethesda, MD 20892. The statutory authority for this sole source requirement is 41 U.S.C.1901 (e) (2) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR QUOTES. All responsible sources that could provide comparable services may submit a capability statement that will be considered by email (subject line to reference NOI-NIAID-2031238) to Ms. Skye Duffner at skye.duffner@nih.gov by 10:00 pm eastern standard time, August 20, 2020. All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.
- Web Link
-
SAM.gov Permalink
(https://beta.sam.gov/opp/d5a0ae89c6b148b391563bff5e404eb3/view)
- Place of Performance
- Address: Bethesda, MD 20892, USA
- Zip Code: 20892
- Country: USA
- Zip Code: 20892
- Record
- SN05753525-F 20200813/200811230149 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |